An error occurred retrieving publication content to display, please try again.
Page not found (404)
Sorry - the page you requested could not be found.
Please choose a page from the navigation or try a website search above to find the information you need.
Toolkit
Study found that, despite some concerns, the use of neuraminidase inhibitors in at-risk populations appeared to be a cost-effective approach for the treatment of influenza, and when data were available for adverse events and complication rates, there was little overall difference associated with the use of either zanamivir or oseltamivir when compared individually with placebo
1 Centre for Reviews and Dissemination, University of York, , UK
2 Centre for Health Economics, University of York, , UK
3 Academic Unit of Primary Health Care, Department of Community Based Medicine, University of Bristol, , UK
4 Department of Health Sciences, University of Leicester, , UK
5 Birmingham Research Unit of the Royal College of General Practitioners, , UK
6 Department of Infection, Immunity and Inflammation, University of Leicester, , UK
* Corresponding author Email: jb67@york.ac.uk
Funding: {{metadata.Funding}}
{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}
https://doi.org/{{metadata.DOI}}
Citation:{{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al. ' : ''}}. {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})
Report Content
The full text of this issue is available as a PDF document from the Toolkit section on this page.
The full text of this issue is available as a PDF document from the Toolkit section on this page.
Responses to this report
No responses have been published.
An error has occurred in processing the XML document